Revenue
$94.19B
Fiscal year ended 2025-12-28Operating income
Unavailable
Fiscal year ended 2025-12-28Free cash flow
$19.70B
Fiscal year ended 2025-12-28JOHNSON & JOHNSON (JNJ) reported revenue of $94.19B and net income of $26.80B for the fiscal year ended 2025-12-28. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from JOHNSON & JOHNSON’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | 2021-01-03 | 2019-12-29 | 2018-12-30 | 2017-12-31 | 2017-01-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B |
| Cost of revenue | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B |
| Research & development | $109.00M | $1.84B | $483.00M | $0 | $0 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 2.43B | shares 2.43B | shares 2.56B | shares 2.66B | shares 2.67B | shares 2.67B | shares 2.68B | shares 2.73B | shares 2.75B | shares 2.79B |
| Pretax income | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B | $16.50B | $17.33B | $18.00B | $17.67B | $19.80B |
| Income tax expense | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.70B | $16.37B | $3.26B |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 |
| Selling, general & administrative | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B | $21.52B | $20.07B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | 2021-01-03 | 2019-12-29 | 2018-12-30 | 2017-12-31 | 2017-01-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.71B | $24.10B | $21.86B | $12.89B | $14.49B | $13.98B | $17.30B | $18.11B | $17.82B | $18.97B |
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B | $157.30B | $141.21B |
| Current assets | $55.62B | $55.89B | $53.50B | $55.29B | $60.98B | $51.24B | $45.27B | $46.03B | $43.09B | $65.03B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B | $93.20B | $97.14B | $70.79B |
| Current liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B | $42.49B | $35.96B | $31.23B | $30.54B | $26.29B |
| Total equity incl. NCI | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B | $60.16B | $70.42B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $14.19B | $12.44B | $11.18B | $10.27B | $10.39B | $9.34B | $9.02B | $8.60B | $8.76B | $8.14B |
| Accounts receivable | $17.18B | $14.84B | $14.87B | $14.04B | $15.28B | $13.58B | $14.48B | $14.10B | $13.49B | $11.70B |
| Goodwill | $48.77B | $44.20B | $36.56B | $36.05B | $25.44B | $36.39B | $33.64B | $30.45B | $31.91B | $22.80B |
| Long-term debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B | $32.64B | $26.49B | $27.68B | $30.68B | $22.44B |
| Accounts payable | $11.99B | $10.31B | $9.63B | $9.89B | $11.06B | $9.50B | $8.54B | $7.54B | $7.31B | $6.92B |
Cash flow
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | 2021-01-03 | 2019-12-29 | 2018-12-30 | 2017-12-31 | 2017-01-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B | $21.06B | $18.77B |
| Capital expenditures | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B | $3.28B | $3.23B |
| Investing cash flow | -$23.59B | -$18.60B | $878.00M | -$12.37B | -$8.68B | -$20.82B | -$6.19B | -$3.17B | -$14.87B | -$4.76B |
| Financing cash flow | -$5.54B | -$3.13B | -$15.82B | -$8.87B | -$14.05B | -$6.12B | -$18.02B | -$18.51B | -$7.67B | -$8.55B |
| Net change in cash | -$4.40B | $2.25B | $7.73B | -$360.00M | $502.00M | -$3.32B | -$802.00M | $283.00M | -$1.15B | $5.24B |
| Stock-based compensation | $1.35B | $1.18B | $1.16B | $1.14B | $1.14B | $1.00B | $977.00M | $978.00M | $962.00M | $878.00M |
| Common dividends paid | $12.38B | $11.82B | $11.77B | $11.68B | $11.03B | $10.48B | $9.92B | $9.49B | $8.94B | $8.62B |
| Common share repurchases | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B | $3.22B | $6.75B | $5.87B | $6.36B | $8.98B |
| Depreciation & amortization | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B | $5.64B | $3.75B |
Derived
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | 2021-01-03 | 2019-12-29 | 2018-12-30 | 2017-12-31 | 2017-01-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B | $18.53B | $17.78B | $15.54B |
| Gross margin | 67.9% | 69.1% | 68.8% | 69.3% | 70.3% | 65.6% | 66.4% | 66.8% | 66.7% | 69.7% |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | 20.9% | 22.3% | 21.4% | 21.5% | 25.1% | 24.4% | 24.3% | 22.7% | 23.3% | 21.6% |
| SBC / revenue | 1.4% | 1.3% | 1.4% | 1.4% | 1.4% | 1.2% | 1.2% | 1.2% | 1.3% | 1.2% |
| Current ratio | 1.03x | 1.11x | 1.16x | 0.99x | 1.35x | 1.21x | 1.26x | 1.47x | 1.41x | 2.47x |
| Revenue YoY growth | 6.0% | 4.3% | 6.5% | 1.6% | -4.7% | 0.6% | 0.6% | 6.7% | 6.3% | Unavailable |
| Net margin | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% |
| R&D / revenue | 0.1% | 2.1% | 0.6% | 0.0% | 0.0% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 5.1% | 5.0% | 5.3% | 5.0% | 4.6% | 4.1% | 4.3% | 4.5% | 4.3% | 4.5% |
| Long-term debt / equity | 0.48x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 17.7% | 15.7% | 11.5% | 15.4% | 7.2% | 10.8% | 12.7% | 15.0% | 92.6% | 16.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JNJ in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-04-22View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-10-22View SEC filing
10-Q · Filed 2025-07-24View SEC filing
10-Q · Filed 2025-04-23View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.